Citing EpiPen Price Hike, Clinton Touts Value-Based Pricing Plan

Democratic Presidential Nominee Hillary Clinton weighed in on Mylan Pharmaceuticals' controversial price increase for EpiPens by touting her plan to invest in private comparative value and benefits research and use the results to hold drug companies accountable for justifying their price hikes. She called on Mylan to immediately reduce the price of EpiPens in a statement Wednesday (Aug. 24), saying there is no apparent justification for the cost. A day after Clinton blasted the company, Mylan announced it is reducing...